Repligen | RGEN - Ebitda


Repligen reported $35.93M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agilent USD 466M 5M Jun/2025
Align Technology USD 183.84M 19.77M Sep/2025
Bio Techne USD 103.42M 7.47M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Bruker USD 211.6M 207.4M Dec/2025
Charles River Laboratories USD 258.06M 24.83M Dec/2025
Danaher USD 2.13B 252M Dec/2025
Dentsply International USD 167M 30M Sep/2025
Exact Sciences USD 135.42M 2.8M Sep/2025
General Electric Aerospace USD 3.04B 185M Sep/2025
Henry Schein USD 295M 39M Sep/2025
Illumina USD 332M 12M Sep/2025
IQVIA Holdings USD 1.05B 97M Dec/2025
Mettler Toledo International USD 322.64M 26.75M Sep/2025
Myriad Genetics USD 10.3M 4.2M Sep/2025
OraSure Technologies USD 920K 9.87M Jun/2024
Pacific Biosciences Of California USD -73.24M 3.12M Sep/2023
Pfizer USD 6.08B 351M Sep/2025
Repligen USD 35.93M 3.75M Sep/2025
Revvity USD 248.91M 48.52M Dec/2025
Standard Biotools USD -16.54M 2.26M Sep/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
Waters USD 380.97M 85.83M Dec/2025
West Pharmaceutical Services USD 218.5M 5.4M Dec/2025